has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its OptiCross™ Coronary Imaging Catheter and has launched the device in the U.S. and Europe. A launch in ...
The addition of IVUS to a fixed-dose catheter thrombolysis regimen failed to facilitate thrombus resolution in patients with acute iliofemoral deep vein thrombosis in the BERNUTIFUL trial. The ...
NATICK, Mass., July 24, 2013 /PRNewswire/ -- The Boston Scientific Corporation has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its OptiCross(TM) Coronary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results